medwireNews: Neoadjuvant treatment with nivolumab plus ipilimumab, followed by response-driven adjuvant therapy, significantly improves the event-free survival (EFS) of patients with stage III melanoma relative to standard of care adjuvant immunotherapy, indicates the NADINA trial presented at the 2024 ASCO Annual Meeting.
04-06-2024 | Melanoma | Editor's Choice | News